Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Clinical trial NCT06325683 · SUSPENDED
Trial details
- NCT number
- NCT06325683
- Sponsor
- National Cancer Institute (NCI)
- Status
- SUSPENDED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-08
- Primary completion
- 2028-07-15
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.